Accepted for/Published in: JMIR Research Protocols
Date Submitted: Nov 9, 2024
Open Peer Review Period: Nov 13, 2024 - Jan 8, 2025
Date Accepted: May 30, 2025
(closed for review but you can still tweet)
Effect of dual bronchodilation on the exercise capacity of individuals with non-cystic fibrosis bronchiectasis: A randomized controlled double-blind cross-over study protocol
ABSTRACT
Background:
Bronchodilators (BDs) have been used therapeutically to improve exercise capacity in patients with other chronic respiratory diseases. However, the effect of BDs on the exercise capacity of individuals with non-cystic fibrosis bronchiectasis (NCFB) is poorly understood.
Objective:
To evaluate the effects of BDs on exercise capacity and thoracoabdominal kinematics in patients with NCFB.
Methods:
This crossover randomized controlled trial will involve 45 outpatients with NCFB aged 18 to 59 years. They will be evaluated in three visits. On Day 1, the maximal exercise capacity (cardiopulmonary exercise test) (Wpeak) will be assessed. On Day 2, individuals will be randomized to receive either BDs (ipratropium bromide 160 µg and fenoterol hydrobromide 400 µg) or a placebo and then undergo simultaneous endurance exercise capacity (constant work-rate exercise test) and thoracoabdominal kinematics (TK) (optoelectronic plethysmography) assessments. After a one-week washout (Day 3), the individuals will repeat the same assessments as on Day 2, in reverse order. The time to the limit of tolerance (Tlim) will be obtained in both groups (the BD and placebo groups) as the primary outcome. TK will be assessed at three time points: at rest, during unloaded exercise, and at 75%Wpeak. The total chest wall and compartmental volumes, as well as thoracoabdominal asynchrony, will be assessed. The assessors and patients will be blinded to the interventions (BDs or placebo). Data will be compared using t tests or Wilcoxon tests and repeated-measures ANOVA or Friedman tests. Categorical data will be analysed using the chi-square test or Fisher’s test. The associations among variables will be analysed using Pearson or Spearman correlation. The significance level will be set at 5% (P<.05).
Results:
The ethics approval was granted in November 2018, and a pilot study was commenced in April 2019 but was interrupted due to the COVID-19 pandemic. The study restarted in April 2022 and data collection is ongoing, which is anticipated to continue until July 2025. Publication of results is anticipated from 2025 to 2026.
Conclusions:
There is no evidence that bronchodilators can improve the NCFB patients’ exercise capacity. This trial will compare the endurance exercise capacity of the same individual with and without dual bronchodilation. If successful, this study will demonstrate that exercise capacity can be improved with the use of bronchodilators in adults with NCFB. Clinical Trial: ClinicalTrials.gov NCT05183841; https://clinicaltrials.gov/study/NCT05183841
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.